用天然化合物向牛皮炎症:机械学见解和治疗承诺
Aya M Mustafa1, Ahmed M Atwa2,3, Ali M Elgindy2
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt. aya-mustafa@eru.edu.eg.
Inflammopharmacology
|July 21, 2025
概括
天然产品通过向炎症和免疫反应,提供有前途的抗皮病潜力. 为了在牛皮管理中临床使用,需要进一步研究标准化和交付.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 牛皮是一种慢性,免疫介导的皮肤疾病,具有不受控制的角质细胞生长和炎症.
- 目前的生物疗法面临诸多挑战,包括成本,安全问题和治疗耐药性.
- 越来越需要替代性和补充性牛皮治疗方法.
研究的目的:
- 审查用于治疗牛皮的天然产品的药理基础.
- 探索天然化合物对抗牛皮病途径的多目标机制.
- 评估植物化学品在牛皮管理中作为辅助剂或替代品的潜力.
主要方法:
- 关于天然产品和牛皮的临床前和临床研究的文献综述.
- 分析关键的植物化学物质 (如黄素,氨酸) 和它们的作用机制.
- 检查对牛皮路径 (例如NF-κB,IL-23/Th17轴) 和氧化应激的影响.
主要成果:
- 自然化合物表现出与牛皮相关的抗炎,抗氧化,抗增殖和免疫调节作用.
- 植物化学物质调节关键的牛皮路径,显示出降低牛皮区域和严重性指数 (PASI) 评分的潜力.
- 研究表明,这些药物可以减轻免疫过活,并提高传统治疗的安全性/有效性.
结论:
- 天然产品显示出作为补充或替代牛皮治疗剂的显著治疗潜力.
- 克服标准化和药理动力学等翻译挑战对于临床整合至关重要.
- 先进的研究,包括奥米克和配方技术,将支持开发基于自然的牛皮治疗方法.
相关概念视频
Inflammatory Response
7.7K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
7.7K
Inflammatory Bowel Disease IV: Pharmacological Management
196
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
196
T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
The JAK-STAT Signaling Pathway
9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
236
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
236
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
257
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
257


